Wright medical group n.v. (WMGI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Jan'12Jan'11Dec'09
Operating activities:
Net loss

-114,225

-169,505

-202,598

-432,373

-298,701

-29,471

-36,426

-21,744

-30,456

-39,509

-55,686

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization

-

-

-

-

-

40,623

36,566

30,232

28,107

27,038

29,732

Impairment of fixed assets

-

-

-

-

-

-

140

2,041

-

-

-

Lease termination costs

-

-

-

-

-

-

-

731

-

-

-

Intangible impairment

-

-

-

-

-

-

-

4,737

-

-

-

Non-cash foreign currency loss

-

-

-

-

-

-1,087

-1,829

495

-298

-7,143

3,898

Depreciation

64,149

59,497

56,832

55,800

-

-

-

-

-

-

-

Depreciation

-

-

-

56,782

29,481

-

-

-

-

-

-

Share-based compensation expense

32,567

26,120

19,393

14,416

24,964

9,701

8,300

6,830

6,547

5,630

3,913

Amortization of intangible assets

31,921

26,730

28,396

29,180

16,922

-

-

-

-

-

-

Tax benefit from reversal of valuation allowance

-

-

-

-

-

-146

-1,120

-10,700

-

-

-

Amortization of deferred financing costs and debt discount

54,461

54,630

50,379

40,487

27,600

775

969

524

2,040

19,612

17,202

Deferred income taxes

-2,464

-4,543

-13,791

20,583

3,087

-7,893

3,566

-4,506

-11,619

-6,548

-11,807

Inventory Write-down

13,126

20,913

19,171

22,046

14,218

11,433

8,447

8,171

4,996

5,212

6,781

Inventory Step Up Amortization Expense

1,057

352

0

-

-

-

-

-

-

-

-

InventoryStepUpAmortizationExpense

1,057

352

0

41,503

11,356

-

-

-

-

-

-

Non-cash adjustment to derivative fair values

-10,962

35,934

-4,797

-28,273

-10,045

-

-

-

-

-

-

Net loss on exchange of cash convertible notes

14,274

39,935

0

12,343

25,101

-

-

-

-

-

-

Non-cash asset impairment

5,597

0

0

-

-

-

-

-

-

-

-

Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax

-

-

-

-21,342

0

-

-

-

-

-

-

Mark-to-market adjustment for CVRs

-420

140

5,320

8,688

-7,571

-5,388

-5,140

-

-

-

-

Loss Contingency, Receivable, Period Increase (Decrease)

-

-

-

0

25,000

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-1,127

-593

-29,475

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-172

28,027

Incentive related to new facility lease

-

-

-

-

-

-

-

1,400

-

-

-

Acquired inventory step up

-

-

-

-

-

577

5,908

1,993

-

-

-

Other

-7,322

1,617

-1,385

-4,425

-4,780

-908

-1,095

-1,836

186

-1,871

-2,062

Changes in assets and liabilities (net of acquisitions):
Accounts receivable

6,989

8,223

-2,483

1,118

13,078

11,100

1,084

2,188

4,673

-3,790

-425

Inventories

32,866

35,887

29,526

187

24,695

21,619

9,186

3,057

7,939

-17,349

13,927

Prepaid expenses and other current assets

-7,106

-45,712

22,744

-22,441

10,471

-

-

-

-

-

-

Accounts payable

-15,866

6,022

6,260

1,495

-2,919

-

-

-

-

-

-

Accrued expenses and other liabilities

-27,822

14,839

21,834

-11,251

23,258

-

-

-

-

-

-

CVR product sales milestone payment

0

-42,044

0

-

-

-

-

-

-

-

-

Metal-on-metal product liabilities

-34,003

-103,056

-79,139

-

-

-

-

-

-

-

-

Payment of Contingent Consideration

-

-

-

-

-27,983

-

-

-

-

-

-

Increase (Decrease) in Metal on Metal Product Liability Accrual

-

-

-

256,461

0

-

-

-

-

-

-

Net cash provided by (used in) operating activities

41,607

-63,729

-184,810

37,824

-195,870

1,008

24,982

14,431

23,166

2,889

2,291

Investing activities:
Additions of instruments

-

-

-

-

-

83

2,935

1,410

3,142

2,328

-

Additions of instruments

-

-

-

-

-

21,751

23,805

11,999

19,734

13,838

12,339

Property, plant and equipment lease incentive

-

-

-

-

-

-

-

1,400

-

-

-

Capital expenditures

99,286

71,467

63,474

50,099

43,666

10,494

10,825

9,891

6,599

6,687

11,109

Purchase of intangible assets

8,448

2,483

2,099

4,845

82

-

-

-

-

-

-

Accounts payable and accruals

-

-

-

-

-

12,489

7,421

87

2,573

2,348

497

Other current assets and liabilities

-

-

-

-

-

3,190

-4,704

1,526

-3,987

307

870

Other non-current assets and liabilities

-

-

-

-

-

-2,222

2,134

-65

194

-1,710

160

Acquisition of business

-722

434,289

44,128

0

4,905

2,000

8,665

102,612

-

-

7,656

Other investing

-3,766

2,000

-280

-

-

-

-

-

-

-

-

Cash Acquired from Acquisition

-

-

-

-

30,117

-

-

-

-

-

-

Sales and maturities of available-for-sale marketable securities

-

-

-

-

2,566

-

-

-

-

-

-

Proceeds from sale of assets

-

-

-

-

0

-

-

-

-

-

-

Proceeds from Divestiture of Businesses

-

-

-

20,703

0

-

-

-

-

-

-

Net cash used in investing activities

-103,246

-510,239

-109,421

-34,241

-15,970

-34,328

-46,230

-125,795

-29,475

-22,853

-31,104

Financing activities:
Issuance of ordinary shares

52,076

21,618

27,551

8,460

3,513

3,976

21,481

7,710

-

819

-

Proceeds from equity offering

0

448,900

0

-

-

-

-

-

-

-

-

Repayment of notes payable

-

-

-

-

-

-

-

-

-116,108

-

-

Proceeds from long-term debt

-

-

-

-

-

477

1,796

121,045

5,032

11,361

6,030

Contingent consideration payments

-

-

-

-

-

6,944

1,483

-

-

-

-

Deferred financing costs

-

-

-

-

-

-

111

5,396

2,731

3,534

-

Proceeds from issuance of notes payable and warrants

-

-

-

-

-

-

-

-

-

-

49,332

Payment of equity offering costs

0

25,896

0

-

-

-

-

-

-

-

-

Issuance of stock warrants

21,210

102,137

0

54,629

87,072

-

-

-

-

-

-

Payment of notes premium

0

-55,643

0

-

-

-

-

-

-

-

-

Payment of notes hedge options

30,144

141,278

0

-

-

-

-

-

-

-

-

Payments of long term borrowings

-

-

-

99,816

144,843

-

-

-

-

-

-

Repurchase of stock warrants

11,026

23,972

0

3,319

59,803

-

-

-

-

-

-

Settlement of 2017 Notes Conversion Derivative

-

-

-

-1,619

-49,152

-

-

-

-

-

-

Payment of equity issuance costs

350

1,870

0

-

-

-

-

-

-

-

-

Proceeds from notes hedge options

16,849

34,553

0

3,892

69,764

-

-

-

-

-

-

Proceeds from exchangeable senior notes

0

675,000

0

-

-

-

-

-

-

-

-

Repayments of Assumed Debt

-

-

-

0

81,367

-

-

-

-

-

-

Proceeds From Cash Settled Convertible Debt

-

-

-

425,821

632,500

-

-

-

-

-

-

Proceeds from other debt

4,511

25,243

34,901

-

-

-

-

-

-

-

-

Proceeds from sale of property, plant and equipment

-

-

-

-

-

-

-

1,517

-

-

-

Change in short-term debt

-

-

-

-

-

6,000

-1,000

-8,009

-10,513

6,468

-3,506

Payments of debt

4,695

38,637

11,517

0

0

1,092

54,095

28,684

8,147

7,687

9,881

Redemption of convertible senior notes

0

400,911

0

102,974

240,000

-

-

-

-

-

-

Payment of financing costs

2,981

14,701

0

10,110

20,081

-

-

-

-

-

-

2023NotesEquityIssuanceCosts

-

-

-

998

-

-

-

-

-

-

-

Payment of contingent consideration

-207

-919

-1,429

-1,035

-70,120

-

-

-

-

-

-

Payments of finance lease obligations

7,837

5,508

2,690

2,514

621

-

-

-

-

-

-

Proceeds from issuance of ordinary shares

-

-

-

-

-

283

78,952

-

171,577

-

2,882

Net cash (used in) provided by financing activities

37,406

598,140

46,816

270,417

126,862

2,700

45,540

86,666

39,110

7,427

44,857

Effect of exchange rates on cash and cash equivalents

-262

-561

2,890

-1,539

-2,544

1,776

1,384

1,100

-2,933

-594

577

Net decrease in cash and cash equivalents

-24,495

23,611

-244,525

272,461

-87,522

-28,844

25,676

-23,598

29,868

-13,131

16,621

Capitalized software development costs

-

-

-

-

-

-

1,180

-

-

-

-

Supplemental disclosure:
Fixed assets acquired pursuant to capital lease

-

-

-

-

-

1,236

42

560

640

614

-

Income taxes paid

-

-

-

-

-

2,034

1,700

2,937

1,119

999

-2,163

Interest paid

-

-

-

-

-

4,185

6,043

2,084

2,235

2,193

1,854